Genomic Landscape of Human Papillomavirus–Associated Cancers

Maria Rusan1,2,3,4, Yvonne Y. Li3,4, and Peter S. Hammerman3,4

Abstract

Recent next-generation sequencing studies have generated a comprehensive overview of the genomic landscape of human papillomavirus (HPV)–associated cancers. This review summarizes these findings to provide insight into the tumor biology of these cancers and potential therapeutic opportunities for HPV-driven malignancies. In addition to the tumorigenic properties of the HPV oncoproteins, integration of HPV DNA into the host genome is suggested to be a driver of the neoplastic process. Integration may confer a growth and survival advantage via enhanced expression of viral oncoproteins, alteration of critical cellular genes, and changes in global promoter methylation and transcription. Alteration of cellular genes may lead to loss of function of tumor suppressor genes, enhanced oncogene expression, loss of function of DNA repair genes, or other vital cellular functions. Recurrent integrations in RAD51B, NR4A2, and TP63, leading to aberrant forms of these proteins, are observed in both HPV-positive head and neck squamous cell carcinoma (HNSCC) and cervical carcinoma. Additional genomic alterations, independent of integration events, include recurrent PIK3CA mutations (and aberrations in other members of the PI3K pathway), alterations in receptor tyrosine kinases (primarily FGFR2 and FGFR3 in HPV-positive HNSCC, and ERBB2 in cervical squamous cell carcinoma), and genes in pathways related to squamous cell differentiation and immune responses. A number of the alterations identified are potentially targetable, which may lead to advances in the treatment of HPV-associated cancers. Clin Cancer Res; 21(9); 2009–19. ©2015 AACR.

Introduction

Late in 1979, Lutz Gissmann and Ethel-Michele de Villiers, working in the laboratory of Harald zur Hausen, successfully isolated and cloned the first human papillomavirus (HPV) DNA from genital warts: HPV6. HPV11 was cloned shortly thereafter from a laryngeal papilloma. The German research group hypothesized that HPV was the causative agent in cervical cancer. By using HPV11 as a probe, one of 24 cervical cancer biopsies was found to be positive. In addition, several of the other biopsies yielded faint bands, allowing speculation that these might represent the presence of related HPV types. Only a few years later, in 1983, the group isolated HPV16 DNA, and in 1984, HPV18 DNA, which they noted were present in about 50% and 20% of cervical cancer biopsies, respectively, as well as in several cervical cancer cell lines. Harald zur Hausen received the Nobel Prize in Physiology or Medicine in 2008 for the groundbreaking discovery of his group.

Now, over 30 years later, HPV is known to be the etiologic agent in cervical cancer, as well as in a significant proportion of anogenital cancers and head and neck squamous cell carcinoma (HNSCC) cases (in particular tonsillar and base of tongue carcinomas; refs. 1, 2). HPV is further responsible for a variety of benign neoplasms, such as genital warts, oral papillomas, and recurrent respiratory papillomatosis. More than 150 HPV types have been identified and classified into low-risk and high-risk based on their malignant potential. The predominant high-risk type identified in cervical, anogenital, and head and neck carcinomas is HPV16.

HPV infects epithelial tissue and depends on epithelial differentiation for completion of its life cycle (3, 4). The molecular biology of HPV during its normal life cycle and in carcinogenesis is described in several recent reviews (3, 5–9). HPV is known to drive tumorigenesis in particular through the actions of the oncoproteins E6 and E7 (10–12). These target numerous cellular pathways, such as p53 and pRB, to promote cellular immortalization, thus providing an environment amenable to viral replication. Furthermore, the virus has adapted multiple mechanisms to evade the host immune response. These include expression of viral proteins at high levels only in the upper epithelial layers where immune surveillance is limited and nonlytic release of virions without significant viraemia, through the natural epithelial shedding process. HPV further hampers the immune system by hindering Langerhans cell migration (13, 14) and activation (15), by suppressing the IFN response (16, 18), and by interfering with HLA class I–mediated antigen presentation (19). Persistent infection with HPV leads to an environment of genomic instability and local immune suppression, which can lead to both the accumulation of genomic alterations in the host cell, as well as to the integration of the viral genome into the host genome. When these additional alterations provide a selective growth advantage to the cell, carcinogenesis may ensue.

Recent genome-wide studies (20–24) using next-generation sequencing techniques (whole genome/exome sequencing, RNA-Seq, miRNA-Seq) and methylation analyses, have described the genomic and epigenomic alterations of HPV-associated cancer.
cancers. These comprehensive studies have generated novel information about how HPV integration may drive genomic instability and the progression from viral infection to cancer, as well as highlighted genomic aberrations that may be targetable in the treatment of HPV-associated cancers. This review summarizes the recent literature concerning the genomic landscape of HPV-associated cancers, and the interactions between HPV and the host genome in cancer.

Characterization of HPV Integrations

During an infection, HPV genomes are found in the nucleus as episomes (circular, extrachromosomal DNA). Integration of the viral genome, or fragments thereof, into the host genome has been noted in the majority of high-grade cervical lesions and cancers (25–28). Thus, it is believed that integration occurs relatively late in the progression to high-grade cervical dysplasia. Integration has also been noted in a significant proportion of HPV-positive HNSCCs (22, 29). It has been suggested that integration disrupts the E2 open reading frame causing upregulated expression of the E6 and E7 oncoproteins (refs. 30, 31; E2 normally suppresses their expression). Furthermore, the integrated viral transcripts confer stronger transforming capacity than those derived from episomes, due to longer half-life of transcripts (32). This promotes immortalization and transformation of these cells and provides a selective growth advantage (3, 8, 30, 33). Integration may, however, confer a selective growth advantage to the host cells not only through its effects on the viral genome (i.e., enhanced/deregulated expression of viral oncoproteins), but also through its effects on the host genome (i.e., by affecting key cellular genes).

Akagi and colleagues (23) undertook an analysis of a panel of ten cervical and head and neck cancer cell lines (five HPV16-positive and three HPV-negative HNSCC lines, and two HPV-positive cervical lines), as well as two HPV-positive primary HNSCC samples. The HNSCC HPV-positive lines were from the following anatomic sites: oral cavity (n = 1), hypopharynx (n = 1), larynx (n = 1), tongue (n = 2), and tonsillar fossa (n = 1). The two primary samples were from an oral cavity carcinoma and a tonsillar carcinoma. Samples were analyzed by whole-genome sequencing, RNA-seq, spectral karyotyping, FISH, and other molecular assays. The majority of the lines and the two primary samples had less than 10 breakpoints in the host genome. Two of the cancer cell lines, however, had a high number of breakpoints (CaSki, a cervical carcinoma line, had 47, and UPCI:SCC090, a tongue SCC line, had 33). Akagi and colleagues found that breakpoints occurred throughout the viral genome, frequently fragmenting the viral genome and leading to loss of viral genes. In four of nine cell lines, E2 was missing. E6 and E7 were, however, retained and expressed in all cases. Of note, E6 and E7 were amplified within the viral–host concatamers in most samples.

Parfenov and colleagues performed a comprehensive, genome-wide analysis of 35 primary HPV-positive HNSCCs, considering the effect of integrations on the structure of the host genome, RNA expression, and the epigenome (22). Twenty-nine of the 35 tumors (83%) had HPV16, and the remainder had HPV33 or HPV35. Twenty-five of the 35 cases (71%) had integrated HPV DNA into anywhere from one to 16 regions of the human genome (21 cases had HPV16, three HPV33, and one HPV35). Thirteen cases were from the oropharynx, ten from the oral cavity, and two from the larynx. In line with the findings of Akagi and colleagues (23) as well as studies in cervical cancer (34), the breakpoints mapped broadly across the viral genome, however, occurred with higher observed frequency in E1 (Fig. 1). The observed breakpoints in the viral genome were nonrandom, as they were higher than expected by chance in E1, and in all but one case E6 and E7 were intact. Tumors with an integration event were associated with lower levels of HPV E2, E4, and E5, and higher levels of HPV E6 and E7 expression, compared with integration-negative tumors. However, these results, along with those of others (35), suggest that E2 ORF disruption is not mandatory for enhanced viral oncoprotein expression, and that E2 may be down-regulated by additional mechanisms. It is important to note that not all tumors with integrated HPV showed enhanced expression of viral E6 and E7 oncoproteins, indicating that elevated levels may not be essential for the development of cancer. This suggests that HPV integration, or additional genetic alterations, can drive carcinogenesis independently of enhanced E6 and E7 expression, and that in certain cases, constitutive rather than enhanced expression of E6/E7 is sufficient for cancer development.

Interestingly, breakpoints in a specific HPV gene did not correlate with that gene’s expression level in the samples studied by Parfenov and colleagues (22). This may be due to expression from intact HPV copies in the sample. Expression of viral genes after integration may also be influenced by nearby cellular regulatory sequences (36). Conversely, in cervical cancer samples, Ojesina and colleagues (24) observed elevated host gene expression levels at sites of integration compared with expression levels of the same genes in tumors without integration. This was associated, in a proportion of the cases, with copy-number gains, but not at all sites, indicating that expression may be partly driven by the integrated viral promoter(s) at some sites (24).

Integrations occur throughout the human genome in both HNSCC (22, 23) and cervical cancer (refs. 23, 24, 34; Fig. 2). Parfenov and colleagues noted, however, that this is often in regions of microhomology (1–10 bp) among the viral and host genome, and most frequently into genic regions and miRNA regions. In 54% of cases the virus integrated into a known gene and in 17% within 20 kb of a gene. Similarly, Akagi and colleagues observed enrichment of HPV integrants within 50 kb of RefSeq genes. In addition, several studies have found that HPV integrates within, or close to, fragile sites (23, 24, 34). Interestingly, several studies have noted that HPV integrations colocalize with somatic copy number variants, including focal amplifications, deletions, intra- and interchromosomal translocations (22–24). Akagi and colleagues found HPV integrants at regions of amplification (ranging from a 1.5-fold increase in HSM001 cells to a 58-fold increase in UPCI:SCC090 cells), as well as regions with deletions (spanning from 487 bp in HSM001 to 234 kb in chromosome 3 of UPCI:SCC090). They further observed that HPV insertional breakpoints frequently clustered together. Akagi and colleagues suggested a looping model to explain the amplifications and rearrangements noted at integration sites. In this model there is nicking of the host genome, integration of the linear HPV genome, transient formation of circular DNA containing both host and viral sequences, rolling circle amplification of this template and formation of integrated concatamers of viral–host sequences. Parfenov and colleagues further noted amplification events that were suggestive of excision, subsequent circularization of the integrated virus and adjacent human sequences, and maintenance of the fused viral-host genome as an episome. Both Parfenov and colleagues (22) and
Akagi and colleagues (23) noted the expression of virus-host fusion transcripts. Parfenov and colleagues (22) further considered whether integration was associated with clinical outcome or other clinical features (anatomic site, tumor stage, age, smoking status), but did not find any statistically significant associations. However, the sample size was quite limited. In cervical cancer patients treated with radiotherapy, Shin and colleagues (37) found a trend towards decreased disease-free survival in patients with only HPV integrated forms versus patients with both integrated and episomal HPV. Further research is needed to elucidate the relationship between HPV physical status (integrated vs. episomal vs. mixed) and clinical outcome in both HNSCC and cervical cancer.

**Deregulation of Key Cellular Genes by HPV Integration**

Several mechanisms by which HPV integration may confer a selective advantage have been described (Fig. 3). The first of these is loss of function by integration into a gene. Parfenov and colleagues (22), for instance, identified three integration events, in the same primary HNSCC tumor sample, into intron 8 of the RAD51B gene on chromosome 14. RAD51B is a component of the DNA double-strand break repair pathway, and loss of this gene may promote genomic instability. The integration resulted in a 28-fold amplification of a 42 kb segment of intron 8 along with parts of the viral genome. The chimeric construct was circularized, and alternative RAD51B transcripts were expressed that were likely nonfunctional. Intriguingly, integrations in this gene have also been noted in multiple cervical cancer samples by Ojesina and colleagues (24) related to HPV16, HPV18, and HPV52 integrations, and by Khoury and colleagues in HNSCC samples (38). Similarly, integration has been described into ETS2, a tumor suppressor gene, with deletion of exon 7 and 8 at the integration site, resulting in truncated forms of the ETS2 protein (22).

A second mechanism by which integration may lead to deregulation of key cellular genes is by amplification and subsequent overexpression of these genes. In one example, HPV integrated upstream of the NR4A2 oncogene, resulting in a 284-fold amplification of a 75 kb genomic region encompassing the NR4A2 gene, and overexpression of NR4A2. Interestingly, this tumor exhibited low levels of E6 and E7, suggesting that other factors were important for tumorigenesis in this case. Integration near NR4A2 was also noted in one cervical sample by Ojesina and colleagues (24). Additional examples include amplification of the oncogenes FOXE1 and PIM1 in UPCI:SCC090 cells (tongue SCC), and the solute carrier, SLC47A2, in UIM-SCC-104 cells (oral cavity SCC; ref. 23).
Figure 2.
Integration sites of HPV into the human genome. A, integration sites in head and neck squamous cell carcinomas, based on data from the HPV-positive tumors analyzed by Parfenov et al. (22), and integration sites in cervical carcinomas, based on data from Ojesina et al. (B; ref. 24). In both panels, integrations into coding regions are represented by red dots, and noncoding regions by blue dots. If a tumor had multiple insertions at the same locus, it is only represented once in the diagram. Several cases had multiple genes in the region involved in the integration event: aPARN, BFAR, PLA2G10; bERBB2, STARD3, TCAP, PNMT, PGAP3, C17orf37, GRB7, IK2F3; cERBB2, C17orf37, GRB7; dMIRLET7B, MIRLET7BHG, MIRLET7A3, MIR4763.
cervical cancer, several cases of integration near or within the MYC gene locus have also been described (24, 39–41).

Finally, HPV insertion is associated with intra- and inter-chromosomal rearrangements. Parfenov and colleagues described one HNSCC case where there was a rearrangement between chromosomes 3 and 13 near the site of integration. The integration was in a nongenic region; however, the translocation involved a region of chromosome 3 containing tumor protein p63 regulated 1 (TPRG1) and TP63, and on chromosome 13 the Krüppel-like factor 5 (KLF5) gene. The regions involved in the rearrangement were amplified and led to increased expression of KLF5, TP63, and TPRG1. Of note, KLF5 is a transcription factor known to regulate proliferation and has been implicated in a number of cancer types (42). TP63 is a transcription factor, with an important role in epithelial development, and which has been implicated as an important oncogene in squamous cell cancers (43, 44). The function of TPRG1 is not well characterized. Aberrant expression of TP63 secondary to HPV integration was also noted in UM-SCC-47 cells (23) and in cervical cancer (24).

The colocalization of HPV integrations with alterations that may lead to loss or gain of function in key cancer genes, in particular the presence of recurrent integration in specific genes,
highly suggests that integration contributes to tumorigenesis. Further work is, however, needed to more fully characterize and validate the impact of HPV integration on these cellular genes to gain a deeper understanding of the cancer biology in these cases.

**Additional Genomic Alterations in HPV-Associated Cancers**

Additional genomic alterations, not associated with HPV integration events, have been described in HPV-driven cancers. These are believed to contribute to tumor development.

**HNSCC**

Several genome-wide studies of HNSCC have suggested that HPV-driven cases display less genomic complexity compared to HPV-negative cases, which is associated with excessive smoking and alcohol consumption (45). A comprehensive study of 279 HNSCC tumors by the Cancer Genome Atlas group did not confirm this finding (36 of the tumors were HPV-positive, composed of 21 oropharyngeal, 12 oral cavity, one laryngeal, and one hypopharyngeal carcinoma). However, the majority of HPV-positive patients in the study were also smokers, and displayed CpG transversions, a mutation class typically associated with smoking [along with the expected virus-associated Tp/Cp (A/C/T) substitution mutations]. Seiwert and colleagues have shown that smokers (both HPV-negative and HPV-positive) display a higher mutational burden (21). Although HPV-positive status confers a favorable prognosis, patients with >10 pack-year smoking history have a poorer prognosis (46). The increased genomic complexity, the presence of unfavorable alterations (i.e., p53 mutations), as well as changes to the immune environment in tumors associated with smoking may contribute to the poorer prognosis.

Both HPV-positive and negative HNSCC tumors have been shown to have recurrent focal amplifications of 3q26/28, which includes factors involved in squamous lineage transcription, such as TP63 and SOX2, as well as the oncogene, PIK3CA (refs. 20, 21; Fig. 4). In addition to amplification of PIK3CA, mutations in PIK3CA have been also been found to be enriched in HPV-positive HNSCCs in a number of studies (20, 21, 47, 48). Importantly, PIK3CA alterations have been reported to be potential therapeutic biomarkers in this patient population (48). In addition, KRAS, NRAS and HRAS alterations have been reported in about 10% of cases (21). These alterations converge upon NF-κB transcription factors that promote cell survival, migration, inflammation, and angiogenesis. Of note, RAS mutations have been associated with poor outcome in other cancer types (49), as well as resistance to anti-EGFR therapies in non–small cell lung cancer and colorectal cancer (50). The clinical implications of KRAS mutations in HPV-positive tumors are currently unknown.

FGFR2 and FGFR3 mutations have been identified among 17.6% of HPV-positive tumors. FGFR2 mutations include N569D and N569K mutations, and FGFR3 has primarily S249C mutations. Both FGFR2 N569K and FGFR3 S249C have been described in several cancer types, and are sensitive to FGFR inhibitors (51, 52). FGFR–TACC3 fusions, previously identified in

![Signaling pathways deregulated in HPV-associated HNSCC. Red boxes highlight the most frequently altered components. Pathway alterations include homozygous deletions, focal amplifications, and somatic mutations. Data are based on results from TCGA (20) and Seiwert et al. (21).](image-url)
cies and nasopharyngeal carcinomas (55, 56). Other immune signaling, and has been associated with hematologic malignancies and nasopharyngeal carcinomas (20). Deletions and truncating mutations have been described in HPV-negative HNSCC (21). Of note, RAD51B has also been reported as an integration target by multiple studies (22, 24). These alterations, including RAD51B, have also been described in patients with Fanconia anemia. These are patients who are at extreme risk of developing squamous cell carcinomas (57, 58). Alterations in DNA repair genes have been suggested to contribute to the chemo- and/or radiosensitivity of HPV-positive tumors (21).

HPV-positive HNSCC shares many common altered genes and pathways with HPV-negative HNSCC (e.g., NOTCH, MLls, RAS, TP63; refs. 20, 21). Many of these alterations have also been observed in HPV-positive HNSCC cell lines (23). However, unlike in HPV-negative HNSCC, TP53 and CDKN2A are intact in the majority of HPV-positive HNSCC (20-23). Table 1 provides an overview of frequently altered genes in HPV-positive HNSCCs.

Cervical cancer

A recent study employing whole-exome sequencing and transcriptome sequencing in cervical carcinomas found a different pattern of recurrent mutations in cervical squamous cell carcinomas compared to adenocarcinomas (24) (Table 1). Squamous cell carcinomas were found to have a higher rate of nonsilent mutations than adenocarcinomas (4.2 mutations vs. 1.6 mutations per Mb). Similarly to HPV-associated HNSCC, PIK3CA was found to be frequently mutated in cervical squamous cell carcinomas. TP53 and Pten mutations, which are frequently observed in HPV-negative HNSCC, were also identified in cervical squamous cell carcinomas. In addition, recurrent mutations were found in E300, FBXW7, HLA-B, MAPK1, ERBB2, STK11 (also known as LKB1), and NF22L2 in squamous cell carcinomas, and ELF3 and CFBFB in adenocarcinomas (Table 1). The majority of these have been implicated in other cancers as well, for instance E300 and FBXW7 mutations have been identified in both endometrial and head and neck cancers (59, 60), STK11 in lung cancers (61, 62), and ERBB2 in breast (63), gastric, esophageal (64), and lung cancers (65). Interestingly, as in HNSCC, there were mutations in genes involved in antigen presentation, such as HLA-A and β2-microglobulin, and other immune response genes such IFNy and IAK2, suggesting that these alterations may synergize with HPV infection in the pathogenesis of squamous cell carcinomas (24).

### Clinical Perspectives

**Next-generation sequencing techniques for determination of HPV status**

HPV-positive oropharyngeal squamous cell carcinoma has a significantly better prognosis independent of stage at diagnosis compared to HPV-negative oropharyngeal carcinoma (46, 66-74). The latter is primarily associated with heavy tobacco and alcohol exposure. HPV status in non-oropharyngeal HNSCC, including cancers of the oral cavity, hypopharynx, and larynx,

### Table 1. Genes with recurrent somatic mutations in HPV-associated HNSCC and cervical carcinomas

<table>
<thead>
<tr>
<th>Gene</th>
<th>Description</th>
<th>Approximate frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HPV-positive HNSCC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PIK3CA</td>
<td>Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha</td>
<td>22-56</td>
</tr>
<tr>
<td>TRAF3</td>
<td>TNF receptor–associated factor 3</td>
<td>22</td>
</tr>
<tr>
<td>TP53</td>
<td>Tumor protein p53</td>
<td>28</td>
</tr>
<tr>
<td>FGFR3</td>
<td>Fibroblast growth factor receptor 3</td>
<td>11-14</td>
</tr>
<tr>
<td>ML3</td>
<td>Lysine (K)-specific methyltransferase 2C</td>
<td>10</td>
</tr>
<tr>
<td>ML2</td>
<td>Lysine (K)-specific methyltransferase 2B</td>
<td>10</td>
</tr>
<tr>
<td>FLG</td>
<td>Flaggrin</td>
<td>12</td>
</tr>
<tr>
<td>NOTCH1</td>
<td>Notch 1</td>
<td>8-17</td>
</tr>
<tr>
<td>DDX5X</td>
<td>DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked</td>
<td>8</td>
</tr>
<tr>
<td>KRAS</td>
<td>Kirsten rat sarcoma viral oncogene homolog</td>
<td>6</td>
</tr>
<tr>
<td>CYLD</td>
<td>Cylindromatosis (turban tumor syndrome)</td>
<td>6</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal growth factor receptor</td>
<td>6</td>
</tr>
<tr>
<td>Pten</td>
<td>Phosphatase and tensin homolog</td>
<td>6</td>
</tr>
<tr>
<td>DDR2</td>
<td>Discoidin domain receptor 2</td>
<td>2-6</td>
</tr>
<tr>
<td><strong>Cervical squamous cell carcinoma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP300</td>
<td>E1A binding protein p300</td>
<td>16</td>
</tr>
<tr>
<td>PIK3CA</td>
<td>Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha</td>
<td>14</td>
</tr>
<tr>
<td>HLA-B</td>
<td>Major histocompatibility complex, class I, B</td>
<td>9</td>
</tr>
<tr>
<td>TP53</td>
<td>Tumor protein p53</td>
<td>9</td>
</tr>
<tr>
<td>MAPK1</td>
<td>Mitogen-activated protein kinase 1</td>
<td>8</td>
</tr>
<tr>
<td>Pten</td>
<td>Phosphatase and tensin homolog</td>
<td>6</td>
</tr>
<tr>
<td>ERBB2</td>
<td>V-erb-b-2 avian erythroblastoma viral oncogene homolog 2</td>
<td>5</td>
</tr>
<tr>
<td>STK11</td>
<td>Serine/threonine kinase 1</td>
<td>4</td>
</tr>
<tr>
<td>NF22L2</td>
<td>Nuclear factor, erythroid 2-like 2</td>
<td>4</td>
</tr>
<tr>
<td><strong>Cervical adenocarcinoma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ELF3</td>
<td>E74-like factor 3</td>
<td>13</td>
</tr>
<tr>
<td>CBFB</td>
<td>Core binding factor, beta subunit</td>
<td>8</td>
</tr>
</tbody>
</table>

**NOTE:** The approximate frequency with which the genes are mutated in HNSCC is based on data from Seiwert et al. (21) and TCGA (20), and for the cervical carcinomas on data from Ojesina et al. (24).
has not been clearly associated with a similar improved prognosis, suggesting that either HPV may not be playing a major role in pathogenesis of HNSCC outside of the oropharynx or that other features are more important for prognosis at these anatomical sites (72–75). Given the relation to prognosis it is essential to correctly identify HPV-positive cases.

Multiple methods for determining HPV status are available. Immunohistochemistry for p16 expression is used by many centres as a surrogate marker of HPV infection and a prognostic biomarker, as it is a simple and inexpensive assay. The gold standard is detection of E6/E7 mRNA; however, this may be less sensitive depending on the quality of the clinical sample. The use of p16 alone may misclassify a small subset of tumors in which HPV is present and p16 expression has been lost by an independent mechanism. This is of particular relevance in patients that have both HPV and a positive smoking or alcohol abuse history, as p16 may be mutated in these patients. The prognosis of this subgroup of patients requires further examination. Similarly, multiple HPV-positive patients (with and without HPV integration) identified in Parfenov and colleagues (22) had low expression of or absence of E6/E7 expression, and these may be misclassified by E6/E7 mRNA detection.

Next-generation techniques, as described herein, can also detect HPV with high sensitivity (20–23, 76), and has further been suggested to be useful for studying HPV variant epidemiology (76). As these next-generation sequencing methods become increasingly applied in the clinic, it will be important to further define the sensitivity and specificity of these methods for HPV detection and to define which are optimal for clinical use. A discussion of the different methods and their advantages and limitations, as relating to their clinical use, is provided in a number of recent reviews (77, 78). Restricted gene expression and mutation profiling for alterations with well-described clinical significance is most clinically feasible at present. These methods have recently been shown to be applicable also to paraffin-embedded tissue (79) widening the applicability and affordability of these methods.

Genomic landscape of HPV-associated cancers

The studies discussed in the current review have generated considerable insight into the genomic landscape of HPV-associated cancers. Nevertheless, the sample size examined to date remains small for both HNSCC and cervical cancer, and similar studies for other HPV-associated cancers, such as anal, penile, and vulvar cancers have yet to be performed. It is important to emphasize the heterogeneity of HPV-related tumors at different anatomical sites with regards to clinical behavior. The genomic landscape of HPV-associated HNSCC and cervical squamous cell carcinomas described here highlights both similarities and differences. This is consistent with prior studies on chromosomal alterations (80), gene expression patterns (81), and expression of miRNA (82) which demonstrate similarities, but also differences between HPV-positive HNSCC and cervical cancer. Additional studies are needed to further delineate the heterogeneity of these and other HPV-associated tumor types at the genomic level.

Further research is also needed to determine the frequency with which specific alterations occur in these cancers, the role of these alterations in tumorigenesis, and the clinical implications of these alterations. Several of the alterations described herein have been implicated not only in tumor formation, but also in response to therapy, and as such may serve as prognostic biomarkers. RADS1B, a protein involved in DNA repair, is disrupted by HPV integration in both HNSCC and cervical cancer. Deficiency of RADS1B has been shown to sensitize to chemotherapeutic and radiotherapy in vitro models (83) and has been suggested to contribute to the favorable response to therapy of HPV-associated cancers (21). Overexpression of the oncogene NR4A2, which has also been identified as a recurrent integration site, has been shown to confer an unfavorable prognosis in colorectal cancer patients (84). PIK3CA alterations have also been reported as therapeutic biomarkers in HNSCC (48).

Several of the genomic alterations identified are therapeutically targetable, such as mutations in the PI3K pathway in both HNSCC and cervical cancer, FGFR aberrations in HNSCC, and ERBB2 in cervical cancer. Importantly, this could decrease toxicity associated with chemoradiation therapies and sequelae associated with these therapies (85). Trials with PI3K/AKT/mTOR inhibitors are underway in both HNSCC and cervical cancer (refs. 86, 87; NCT02113878, NCT02051751, NCT01602315, NCT02145312). Interestingly, PI3K/mTOR inhibition has previously been shown to sensitize cancer cells to radiation and chemotherapy (88–90). The FGFR3 mutation at position 249 and FGFR3-TACC3 fusions identified in a number of HPV-positive HNSCC cases have shown promising therapeutic response to FGFR inhibitors in preclinical (52) and clinical studies (91, 92). ERBB2 inhibition has well-established therapeutic efficacy in HER2-positive breast cancer and clinical trials are currently underway to consider these agents in cervical cancers with ERBB2 alterations (NCT02342567). Of note, several of the identified alterations are in tumor suppressor genes, which remain a challenge in the design of targeted therapy.

Finally, it is important to note that prophylactic HPV vaccination is available and approved for the prevention of anogenital and cervical carcinoma. It remains to be validated for the prevention of HPV-associated HNSCC; however, early studies suggest the vaccine prevents oral HPV infection (93). Public health strategies to increase vaccination coverage remain the most cost-effective and beneficial approach for reducing disease burden.

Conclusions

HPV infection and subsequent viral protein expression creates an environment suitable for viral replication, whereby keratinocytes are maintained in a proliferative state and the immune system is downmodulated. This environment is also amenable to accumulation of genetic alterations and viral integration, and subsequent tumor formation. Integration affects both the viral genome and the host genome, likely conferring additional neoplastic selective pressure, by one or more of the following mechanisms: (i) enhanced expression of viral oncoproteins, (ii) alteration of critical cellular genes (leading to increased expression of oncogenic proteins, decreased expression of tumor suppressor proteins, altered DNA repair mechanisms, or modulation of the immune system), and (iii) changes in global promoter methylation and transcription.

Comprehensive characterization of genomic alterations in HPV-associated cancers has highlighted multiple potential biomarkers and therapeutic targets. However, the number of HPV-positive tumor samples that have been comprehensively analyzed using genome-wide studies remains small, and larger patient cohorts will be helpful to further detail integration events and other HPV-associated genomic alterations, as well as to study the clinical implications of these aberrations. More detailed studies of
the functional impact of integration on various cellular proteins will be useful in characterizing the cellular pathways that become deregulated and how this leads to tumor progression. Similarly, further research is necessary to understand how distinct methylation patterns arise in HPV-integrated compared with non–HPV-integrated cancers, and the consequences of these patterns on tumor biology and clinical outcomes. Further research regarding the clinical implications of the observed genomic alterations will be imperative for accurate stratification of patients to targeted therapies, radiotherapy and chemotherapy.

References
15. von Knobel Doberitz M, Baulknecht T, Bartsch D, zur Hausen H. Influence of chromosomal integration on glucocorticoid-regulated transcription of


Clinical Cancer Research

Genomic Landscape of Human Papillomavirus–Associated Cancers

Maria Rusan, Yvonne Y. Li and Peter S. Hammerman


Updated version

Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-1101

Cited articles

This article cites 90 articles, 31 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/21/9/2009.full#ref-list-1

Citing articles

This article has been cited by 6 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/21/9/2009.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.